CISH and prostate cancer: They showed that intravenous (i.v.)administration of melanoma cell line (B16/F10) and prostate cancer cell line (RM-1) into CISH-deficient (CISH−/−) NK-cells have significantly reduced melanoma growth and metastatic nodule formation as compared to the wild-type (CISH+/+) mice, indicating the critical role of CISH in NK-cell cytotoxicity.